Microtubule-Targeting Agents Enter the Central Nervous System (CNS): Double-edged Swords for Treating CNS Injury and Disease.
10.5213/inj.2014.18.4.171
- Author:
Eun Mi HUR
1
;
Byoung Dae LEE
Author Information
1. Brain Science Institute, Korea Institute of Science and Technology, Seoul, Korea. ehur@kist.re.kr
- Publication Type:Review
- Keywords:
Microtubules;
Neoplasms;
Nerve Degeneration;
Wounds and Injuries
- MeSH:
Central Nervous System*;
Microtubules;
Nerve Degeneration;
Nervous System;
Neurodegenerative Diseases;
Neurons;
Wounds and Injuries
- From:International Neurourology Journal
2014;18(4):171-178
- CountryRepublic of Korea
- Language:English
-
Abstract:
Microtubules have been among the most successful targets in anticancer therapy and a large number of microtubule-targeting agents (MTAs) are in various stages of clinical development for the treatment of several malignancies. Given that injury and diseases in the central nervous system (CNS) are accompanied by acute or chronic disruption of the structural integrity of neurons and that microtubules provide structural support for the nervous system at cellular and intracellular levels, microtubules are emerging as potential therapeutic targets for treating CNS disorders. It has been postulated that exogenous application of MTAs might prevent the breakdown or degradation of microtubules after injury or during neurodegeneration, which will thereby aid in preserving the structural integrity and function of the nervous system. Here we review recent evidence that supports this notion and also discuss potential risks of targeting microtubules as a therapy for treating nerve injury and neurodegenerative diseases.
